A COVID-19 vaccine candidate composed of SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles - Archive ouverte HAL Access content directly
Journal Articles RSC Chemical Biology Year : 2022

A COVID-19 vaccine candidate composed of SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles

Belinda Sánchez Ramírez
  • Function : Author
Sonia Perez-Rodriguez
  • Function : Author
Tays Hernandez
  • Function : Author
Marianniz Diaz
  • Function : Author
Ivette Orosa
  • Function : Author
Ubel Ramirez
  • Function : Author
Reynaldo Oliva
  • Function : Author
Raine Garrido
  • Function : Author
Felix Cardoso
  • Function : Author
Mario Landys
  • Function : Author
Roselyn Martinez
  • Function : Author
Humberto Gonzalez
  • Function : Author
Tamara Hernandez
  • Function : Author
Rolando Ochoa-Azze
  • Function : Author
Jose Perez
  • Function : Author
Juliet Enriquez
  • Function : Author
Nibaldo Gonzalez
  • Function : Author
Yenicet Infante
  • Function : Author
Luis Ariel Espinosa
  • Function : Author
Yassel Ramos
Luis Javier Gonzalez
  • Function : Author
Carmen Valenzuela
  • Function : Author
Ana Victoria Casadesus
  • Function : Author
Briandy Fernandez
  • Function : Author
Gertrudis Rojas
  • Function : Author
Beatriz Pérez-Massón
  • Function : Author
Yaima Tundidor
  • Function : Author
Ernesto Bermudez
  • Function : Author
Claudia Plasencia
  • Function : Author
Tammy Boggiano
  • Function : Author
Eduardo Ojito
  • Function : Author
Fabrizio Chiodo
Sonsire Fernandez
  • Function : Author
Françoise Paquet
Cheng Fang
  • Function : Author
Guang-Wu Chen
  • Function : Author

Abstract

SARS-CoV-2 infection is mediated by the interaction of the spike glycoprotein trimer via its receptor-binding domain (RBD) with the host's cellular receptor. Vaccines seek to block this interaction by eliciting neutralizing antibodies, most of which are directed toward the RBD. Many protein subunit vaccines require powerful adjuvants to generate a potent antibody response. Here, we report on the use of a SARS-CoV-2 dimeric recombinant RBD combined with Neisseria meningitidis outer membrane vesicles (OMVs), adsorbed on alum, as a promising COVID-19 vaccine candidate. This formulation induces a potent and neutralizing immune response in laboratory animals, which is higher than that of the dimeric RBD alone adsorbed on alum. Sera of people vaccinated with this vaccine candidate, named Soberana01, show a high inhibition level of the RBD-ACE2 interaction using RBD mutants corresponding to SARS-CoV-2 variants of concern and wild-type expressed using the phage display technology. To our knowledge, this is the first time that the immunostimulation effect of N. meningitidis OMVs is evaluated in vaccine candidates against SARS-CoV-2.
Fichier principal
Vignette du fichier
RCSChemBiol2022.pdf (2.81 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-03519898 , version 1 (20-01-2022)
hal-03519898 , version 2 (23-08-2022)

Identifiers

Cite

Darielys Santana, Rocmira Perez Nicado, Yanet Climent, Laura Marta Marta Rodríguez Noda, Belinda Sánchez Ramírez, et al.. A COVID-19 vaccine candidate composed of SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles. RSC Chemical Biology, 2022, 3 (2), pp.242-249. ⟨10.1039/D1CB00200G⟩. ⟨hal-03519898v2⟩
160 View
10 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More